Corporate Profile

Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most, and its hemophilia therapies, when launched, represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit or follow @Bioverativ on Twitter.


Events and Webcasts

Bioverativ to Present at the 2018 J.P. Morgan Healthcare Conference
Monday, January 8, 2018 4:00 p.m. PT

IR Contact

Investor Relations
Phone: 781-663-4360